Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Free Cash Flow rose 10631.45% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 8524.68%. This contributed to the annual value of -$149.0 million for FY2024, which is 1887.83% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Free Cash Flow is $2.2 million, which was up 10631.45% from -$13.4 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Free Cash Flow peaked at $123.6 million during Q3 2021, and registered a low of -$80.7 million during Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was -$39.9 million (2024), whereas its average is -$26.3 million.
  • The largest annual percentage gain for Seres Therapeutics' Free Cash Flow in the last 5 years was 57682.4% (2021), contrasted with its biggest fall of 19439.21% (2021).
  • Seres Therapeutics' Free Cash Flow (Quarter) stood at -$53.4 million in 2021, then decreased by 5.45% to -$56.4 million in 2022, then grew by 14.16% to -$48.4 million in 2023, then increased by 19.44% to -$39.0 million in 2024, then surged by 105.64% to $2.2 million in 2025.
  • Its Free Cash Flow was $2.2 million in Q3 2025, compared to -$13.4 million in Q2 2025 and $26.9 million in Q1 2025.